Isomorphic Labs has raised $5 billion in a Series C round, as the AI drug-discovery company works to advance its drug candidates toward clinical trials. The company says the funding will help scale its drug-design engine, IsoDDE, and its pipeline of medicines designed with AI. TechCrunch reports that the money will also support work on additional types of medicine.
Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz and other new investors joined, while all of Isomorphic’s existing investors also participated, including Alphabet’s GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. Isomorphic did not disclose its valuation. Bloomberg reported earlier in November that the company was seeking a $50 billion valuation, but that figure was not confirmed as part of this announcement.
What is Isomorphic building?
Isomorphic Labs was spun out of Google DeepMind in 2021. Its drug-design engine uses AI models to simulate aspects of chemistry and help design medicines. The work builds on AlphaFold, DeepMind’s system for predicting a protein’s 3D structure from its genetic sequence. TechCrunch reports that Isomorphic says its programs have produced positive preclinical results in oncology and immunology. Preclinical results are from research before testing in people; the company has not announced that these candidates have entered clinical trials.
The company has also struck drug-development deals with Eli Lilly, Novartis and Johnson & Johnson. Those partnerships sit alongside its own candidate pipeline, which the new investment is intended to expand. Isomorphic’s announcement describes the round as funding for its AI advances and medicines pipeline, but it does not provide a timeline for clinical trials or name a candidate set to enter one.
A major new round after May funding
The Series C follows a $2.1 billion Series B round in May, according to TechCrunch. It is also Isomorphic’s first fundraise since founder and CEO Demis Hassabis stepped away from leading DeepMind to focus on drug discovery and took a chairman role there. Hassabis and former DeepMind director John Jumper shared the 2024 Nobel Prize in Chemistry for work on AlphaFold.
The new financing gives Isomorphic more capital to develop its technology and widen its medicine pipeline. But the announcement does not establish when its AI-designed candidates will be tested in people, or whether they will prove safe and effective. Those outcomes will depend on further research and clinical testing.
Why it matters
For people following new treatments, the funding gives Isomorphic more resources to develop AI-designed medicines, including candidates it says have shown positive preclinical results. It does not mean those drugs are in clinical trials or will become available: the company has not named a trial start date or reported results from testing in people.